Abstract:
Myocardial infarction is the main leading cause of mortality world widely. In 2015, it is
predicted that 7.4 million people died as a result of coronary heart disease. CVDs are predicted to
kill 23.6 million individuals by 2030. Decreased or complete obstruction of the blood flow to part
of the myocardium is the main cause of myocardial infarction. For the vast majority of those
suffering from non-ST-segment elevation myocardial infarction (NSTEMI) as opposed to STsegment elevation myocardial infarction, it accounts for more than 15% of mortality each year.
Myocardial infarction encompasses four different mechanisms which are: atherosclerosis
development, deterioration of the formed fibrous plaque, thrombus formation and myocardial cell
death. Tofacitinib is the drug under investigation in this study as it is suggested to have a cytoprotective effect against MI since it acts as inhibitor of the JAKs family which interferes with
JAK/STAT signaling that occur following the inflammation that occur during myocardial
infarction. This study aims to investigate both the relation between kinase inhibitors and
myocardial infarction and the possible cytoprotective effect of Tofacitinib on experimentallyinduced myocardial infarction. In this recent study, 18 albino mice were used and randomly
allocated into three groups. Group (A) was injected with saline only, Group (B) was injected with
Isoprenaline HCl (100mg/kg) subcutaneously for induction of myocardial infarction and Group
(C) was treated with Tofacitinib after receiving isoprenaline for 14 days. The parameters that were
assessed were TNF-ὰ, cardiac troponin I, creatine kinase –MB, STAT-3, Lnc-Xist, NF-κB, mTor,
IL-6 and there was histopathological examination. The results that were obtained from laboratory
investigation of the previous parameters and histopathological examination proved the
cytoprotective effect of Tofacitinib against MI as well as its ability to inhibit the inflammation and
necrosis of the cardiomyctes that occur following the occurrence of MI. Therefore, Tofacitinib
could be a used as a promising treatment and prophylaxis from myocardial infarction
